Vertex Pharma stock trades at EUR 469.05 in weekend trading

Vertex Pharma stock trades in weekend trading at Lang & Schwarz at EUR 469.05 at 5:18 p.m. CEST on October 25, 2026. Vertex Pharmaceuticals Incorporated reported Phase 3 RAINIER results for povetacicept in IgA nephropathy on October 23, 2026, according to the Vertex Pharmaceuticals Newsroom.

Market context: Market report Nasdaq Composite.

Weekend trading

The Lang & Schwarz price was recorded during weekend trading at 5:18 p.m. CEST on October 25, 2026. The next Xetra session is scheduled for October 26, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.

RAINIER trial results

Vertex said the Week 36 interim analysis met its primary endpoint. Povetacicept produced a 52.00% reduction from baseline in proteinuria and a 49.80% reduction versus placebo, with a reported P-value below 0.0001. The company said both secondary endpoints were also met, as reported in its October 23 release.

The release said 42.20% of participants treated with povetacicept reached a 24-hour urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.20% in the placebo group. Vertex also reported that 96.00% of participants in a 25-person qualitative study preferred an autoinjector over a prefilled syringe, while 80.00% preferred dosing every four weeks over weekly dosing.

Upcoming regulatory date

Vertex said the U.S. Food and Drug Administration has accepted the biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy. The company identified November 30, 2026, as the Prescription Drug User Fee Act target action date.